EXOZYMES INC.
corporate_fare Company Profile
EXOZYMES INC. (NASDAQ:EXOZ) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for EXOZ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-13, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for EXOZ spans 10-Q, 8-K, 424B5, 10-K.
Recent high-impact activity:
- eXoZymes 10-Q: Going Concern Warning and Material Weakness Disclosed
- eXoZymes Secures Another $0.64M in Dilutive Unit Offering with Warrant Reset
- EXOZYMES Finalizes $0.64M Unit Offering with Highly Dilutive Warrant Reset Provision
- EXOZYMES Raises $565K in Highly Dilutive Unit Offering with $0.001 Warrant Reset
- eXoZymes Secures $2.03M NIH Grant for Cannabinoid Analog Development, Boosting Non-Dilutive Funding
Financial Snapshot
Short Interest & Short Volume
3.07 days to coverFINRA reported short interest of 20,419 shares in EXOZ as of the September 15, 2026 settlement, a 6.4% decrease from the prior period — about 3.1 days to cover at its recent average daily volume. On October 2, 2026, 36.1% of EXOZ volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for EXOZ, detected from its recent SEC filings · based on capital-structure filings through 2026-07-01.
Unit Offering Completed · Highly Dilutive Warrant Terms
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →